+148.7%
EWY vs MRNA
-67.9%
+216.6%
-43.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.2% | +5.4% | -2.1% | +2.9% |
| 7D | -0.1% | -1.1% | +1.0% | 0.0% |
| 30D | +7.3% | +126.1% | -118.8% | -3.4% |
| 3M | -5.1% | +190.0% | -195.2% | -17.9% |
| 6M | +42.1% | +157.2% | -115.2% | +24.6% |
| YTD | +94.1% | +388.2% | -294.1% | +57.8% |
| 1Y | +147.8% | +467.0% | -319.2% | +96.9% |
| 3Y | +222.9% | +36.1% | +186.8% | +186.7% |
| All | +148.7% | -67.9% | +216.6% | +135.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling